Royalty Pharma Statistics
Share Statistics
Royalty Pharma has 444.30M shares outstanding. The number of shares has increased by -0.54% in one year.
| Shares Outstanding | 444.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.85% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 380.55M |
| Failed to Deliver (FTD) Shares | 290.70K |
| FTD / Avg. Volume | 10.44% |
Short Selling Information
The latest short interest is 15.65M, so 3.52% of the outstanding shares have been sold short.
| Short Interest | 15.65M |
| Short % of Shares Out | 3.52% |
| Short % of Float | 4.11% |
| Short Ratio (days to cover) | 4.83 |
Valuation Ratios
The PE ratio is 11.08 and the forward PE ratio is 5.91.
| PE Ratio | 11.08 |
| Forward PE | 5.91 |
| PS Ratio | 5.34 |
| Forward PS | 3.8 |
| PB Ratio | 1.93 |
| P/FCF Ratio | 4.21 |
| PEG Ratio | n/a |
Enterprise Valuation
Royalty Pharma has an Enterprise Value (EV) of 18.23B.
| EV / Earnings | 16.07 |
| EV / Sales | 7.74 |
| EV / EBITDA | 9.66 |
| EV / EBIT | 12.22 |
| EV / FCF | 6.1 |
Financial Position
The company has a current ratio of 7.9, with a Debt / Equity ratio of 0.94.
| Current Ratio | 7.9 |
| Quick Ratio | 7.9 |
| Debt / Equity | 0.94 |
| Total Debt / Capitalization | 48.46 |
| Cash Flow / Debt | 0.49 |
| Interest Coverage | 7.97 |
Financial Efficiency
Return on equity (ROE) is 0.17% and return on capital (ROIC) is 9.2%.
| Return on Equity (ROE) | 0.17% |
| Return on Assets (ROA) | 0.07% |
| Return on Capital (ROIC) | 9.2% |
| Revenue Per Employee | 31.39M |
| Profits Per Employee | 15.13M |
| Employee Count | 75 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -5.9% in the last 52 weeks. The beta is 0.47, so Royalty Pharma's price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | -5.9% |
| 50-Day Moving Average | 26.07 |
| 200-Day Moving Average | 27.4 |
| Relative Strength Index (RSI) | 53.7 |
| Average Volume (20 Days) | 2.78M |
Income Statement
In the last 12 months, Royalty Pharma had revenue of 2.35B and earned 1.13B in profits. Earnings per share was 3.41.
| Revenue | 2.35B |
| Gross Profit | 1.79B |
| Operating Income | 1.49B |
| Net Income | 1.13B |
| EBITDA | 1.89B |
| EBIT | 1.49B |
| Earnings Per Share (EPS) | 3.41 |
Balance Sheet
The company has 477.01M in cash and 6.14B in debt, giving a net cash position of -5.66B.
| Cash & Cash Equivalents | 477.01M |
| Total Debt | 6.14B |
| Net Cash | -5.66B |
| Retained Earnings | 2.52B |
| Total Assets | 18.04B |
| Working Capital | 626.44M |
Cash Flow
In the last 12 months, operating cash flow was 2.99B and capital expenditures 0, giving a free cash flow of 2.99B.
| Operating Cash Flow | 2.99B |
| Capital Expenditures | 0 |
| Free Cash Flow | 2.99B |
| FCF Per Share | 6.68 |
Margins
Gross margin is 7.62K%, with operating and profit margins of 6.34K% and 4.82K%.
| Gross Margin | 7.62K% |
| Operating Margin | 6.34K% |
| Pretax Margin | 7.22K% |
| Profit Margin | 4.82K% |
| EBITDA Margin | 80.15% |
| EBIT Margin | 63.37% |
| FCF Margin | 126.89% |
Dividends & Yields
RPRX pays an annual dividend of $0.84, which amounts to a dividend yield of 3.26%.
| Dividend Per Share | $0.84 |
| Dividend Yield | 3.26% |
| Dividend Growth (YoY) | 5% |
| Payout Ratio | 33.07% |
| Earnings Yield | 13.2% |
| FCF Yield | 26.03% |
Analyst Forecast
The average price target for RPRX is $41, which is 58.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $41 |
| Price Target Difference | 58.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 1.38 |
| Piotroski F-Score | 6 |